摘要
目的探讨功能医学疗法对甲亢期桥本甲状腺炎(HT)女性患者免疫系统的影响及疗效。方法以随机数表法,将2020年4月至2025年3月收治的60例女性甲亢期HT患者分为对照组(常规疗法,30例)、研究组(常规+功能医学疗法,30例),疗程12周。比较两组甲状腺功能及不良反应。为探索性观察功能医学干预下的免疫动态变化,监测研究组初诊、治疗2周、6周及12周时的免疫功能变化。结果研究组治疗12周后的促甲状腺素(TSH)高于对照组,血清游离三碘甲状腺原氨酸(FT_(3))、游离甲状腺素(FT_(4))、抗甲状腺过氧化物酶抗体(TPOAb)、抗甲状腺球蛋白抗体(TgAb)低于对照组(P<0.05);研究组内部动态监测显示,不同时间节点的TPOAb、TgAb、淋巴细胞百分比(%LYMPH)、CD5^(+)CD19^(+)、CD23^(+)CD19^(+)、CD16^(-)CD56bright^(+)CD3^(-)CD19^(-)比例有统计学意义(P<0.05),其中TPOAb、TgAb、%LYMPH、CD5^(+)CD19^(+)呈持续降低趋势,CD23^(+)CD19^(+)先降后升再降,CD16^(-)CD56bright^(+)CD3^(-)CD19^(-)呈先升后降趋势;两组不良反应率无统计学意义(P>0.05)。结论功能医学疗法可有效改善甲亢期HT女性的甲状腺功能,安全性良好。对研究组的探索性动态监测提示,该疗法可能伴随特定的甲状腺自身抗体及淋巴细胞亚群变化,但其相较于常规治疗的独立效应仍需未来研究进一步验证。
Objective To investigate the effects and efficacy of functional medicine therapy on the immune system in female patients with Hashimoto’s thyroiditis(HT)during the hyperthyroid phase.Methods Using a random number table,60 female patients with HT during the hyperthyroid phase who were treated between April 2020 and March 2025 were assigned to a control group(conventional therapy,n=30)or a study group(conventional therapy plus functional medicine therapy,n=30).The treatment course lasted 12 weeks.Thyroid function and adverse reactions were compared between the two groups.To exploratorily observe immune dynamic changes under functional medicine intervention,immune function in the study group was monitored at the initial visit and at 2,6,and 12 weeks of treatment.Results After 12 weeks of treatment,thyroid-stimulating hormone(TSH)levels were higher in the study group than in the control group,while serum free triiodothyronine(FT_(3)),free thyroxine(FT_(4)),anti-thyroid peroxidase antibody(TPOAb),and anti-thyroglobulin antibody(TgAb)levels were lower in the study group than in the control group(P<0.05).Dynamic monitoring within the study group showed statistically significant differences at different time points in TPOAb,TgAb,lymphocyte percentage(%LYMPH),and the proportions of CD5^(+)CD19^(+),CD23^(+)CD19^(+),and CD16^(-)CD56bright^(+)CD3^(-)CD19^(-)(P<0.05).Specifically,TPOAb,TgAb,%LYMPH,and CD5^(+)CD19^(+)exhibited a continuous downward trend;CD23^(+)CD19^(+)decreased first,then increased,and decreased again;and CD16^(-)CD56bright^(+)CD3^(-)CD19^(-)showed an initial increase followed by a decrease.The incidence of adverse reactions did not differ significantly between the two groups(P>0.05).Conclusion Functional medicine therapy can effectively improve thyroid function in women with HT during the hyperthyroid phase and demonstrates good safety.Exploratory dynamic monitoring in the study group suggests that this therapy may be accompanied by changes in specific thyroid autoantibodies and lymphocyte subsets;however,its independent effect compared with conventional treatment still requires further verification in future studies.
作者
崔昭婷
苏丽
杨杰
马志强
CUI Zhaoting;SU Li;YANG Jie;MA Zhiqiang(Central Laboratory,The Third People’s Hospital of Zhengzhou,Zhengzhou Henan 450000,China;Department of Laboratory Medicine,The Third People’s Hospital of Zhengzhou,Zhengzhou Henan 450000,China;Department of Thyroid and Breast Surgery,The First Affiliated Hospital of Henan University,Kaifeng Henan 475000,China)
出处
《临床研究》
2026年第1期88-92,共5页
Clinical Research
基金
2020年度河南省医学科技攻关计划联合共建项目(LHGJ20200544)。
关键词
桥本甲状腺炎
甲亢期
功能医学疗法
免疫系统
Hashimoto’s thyroiditis
hyperthyroid phase
functional medicine therapy
immune system
